Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1493 • ACR Convergence 2021
Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg¹, Ruediger B. Mueller², Thomas Neumann³, Ian Pirker¹, Philipp Rein⁴, Camillo Ribi⁵, Andrea Rubbert-Roth⁶, Michael Kirschfink⁷, Jutta Schroeder-Braunstein⁷, Reinhard Voll⁸ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St.Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ³Kantonsspital St.Gallen, St.Gallen, Switzerland, ⁴Landeskrankenhaus Hohenems, Wolfurt, Austria, ⁵CHUV, Lausanne, Switzerland, ⁶Kantonspital St Gallen, St.Gallen, Switzerland, ⁷Universitätsklinikum Heidelberg, Heidelberg, Germany, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
Background/Purpose: Few reliable laboratory biomarkers exist to determine disease activity in SLE. The role of the soluble terminal complement complex, sC5b-9, in active SLE has…
Abstract Number: 1594 • ACR Convergence 2021
COVID-19 Pandemic-Related Changes in Health Routines and Self-Reported Physical Functioning Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Brad Pearce¹, S Sam Lim³ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic was disruptive to individual health routines. Changes in health routines may worsen disease management and reduce opportunities for physical activity, both…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 1751 • ACR Convergence 2021
Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Anca Askanase¹, Simrat Randhawa², Laura Lisk³ and Paola Mina-Osorio⁴, ¹Columbia University Medical Center, New York, NY, ²Aurinia Pharmaceuticals Inc., Seattle, WA, ³Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, ⁴Aurinia Pharmaceuticals Inc., New York, NY
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy.…
Abstract Number: 1769 • ACR Convergence 2021
BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects
Manoj Chiney¹, Ihab Girgis², Melanie Harrison¹, Xiaoping Zhang¹, Yun Shen³, Michelle Dawes¹, Lixian Dong², Diane Shevell³, Urvi Aras¹ and Bindu Murthy³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville
Background/Purpose: Toll like receptor (TLR) 7 and TLR8 are activated as part of the disease pathophysiology of systemic lupus erythematosus (SLE), including lupus nephritis (LN),…
Abstract Number: 0130 • ACR Convergence 2021
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
Joseph Tkacz¹, Allison Perry¹, Helen Varker¹, Richard Bizier¹, Robert Ortmann² and Sandra Sze-jung Wu³, ¹IBM Watson Health, Bethesda, MD, ²AstraZeneca, Greenwood, IN, ³AstraZeneca, Wilmington, DE
Background/Purpose: Current literature characterizing the economic and clinical burden of systemic lupus erythematosus (SLE) is outdated and often does not consider SLE disease severity, which…
Abstract Number: 0329 • ACR Convergence 2021
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
ALFREDO AGUIRRE¹, Andrea Seet¹, Laura Trupin², Patricia Katz¹, Kamil Barbour³, Cristina Lanata⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³Centers for Disease Control, Atlanta, GA, ⁴University of California San Francisco, Moss Beach, CA, ⁵University of California San Francisco, Corte Madera, CA
Background/Purpose: Racial and ethnic minorities experience a disproportionate burden of systemic lupus erythematosus (SLE) as well as earlier development of lupus manifestations as compared to…
Abstract Number: 0346 • ACR Convergence 2021
The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products
Joseph Ahearn¹, Susan Manzi¹ and Chau-Ching Liu², ¹Allegheny Health Network, Wexford, PA, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Cell-bound complement activation products (CB-CAPs) have been validated as biomarkers for systemic lupus erythematosus (SLE) diagnosis, monitoring and stratification, and for identification of patients…
Abstract Number: 0495 • ACR Convergence 2021
Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Ali Duarte-Garcia¹, Herbert Heien¹, Nilay Shah¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased burden of multimorbidity. Racial/ethnic disparities have also been associated with an increased burden of multimorbidity.…
Abstract Number: 0602 • ACR Convergence 2021
Use of a Popular Opinion Leader Model to Disseminate Information Virtually About Clinical Trial Enrollment to People of Color with Lupus
Kreager Taber¹, Holly Milaeger², Jessica Williams¹, Daniel Erickson³, Elmer Freeman⁴, Patricia Canessa⁵, Rosalind Ramsey-Goldman⁶ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, MA, ²Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Feinbergy School of Medicine, Chicago, IL, ⁴CCHERS, Inc., Boston, MA, ⁵State of Illinois Board of Health, Chicago, IL, ⁶Northwestern University, Chicago, IL
Background/Purpose: Despite a disproportionate burden of systemic lupus erythematosus (SLE) and disparities in adverse outcomes among Black compared to white individuals, people of color are…
Abstract Number: 0780 • ACR Convergence 2021
High Adolescent Health Needs and Relationship to Disease in Patients with Childhood-Onset Systemic Lupus Erythematosus
Chelsea DeCoste¹, Paris Moaf¹, Lawrence Ng¹, Dragana Ostojic-Aitkens¹, Fatima Faruq², Byran Maguire³, Deborah Levy¹, Linda Hiraki¹, Alene Toulany¹ and Andrea Knight⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE), with typical onset in adolescence, is a chronic life-threatening disease. In addition to dealing with cSLE, these adolescents endure…
Abstract Number: 0870 • ACR Convergence 2021
Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
Shiran Aharon¹, Dafna Ben-Bashat², Orna Aizenstein³, Moran Artzi⁴, Mark Berman⁵, Victoria Furer⁶, Marina Anouk⁷, Yael Lahat⁸, Jonathan Wollman⁹, Ofir Elalouf⁹, Ari Polachek¹⁰ and Daphna Paran¹¹, ¹Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel-Aviv, Israel, ²Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ³Department of Neuroradiology Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁴Wohl Institute of Advanced Imaging, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁵Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Department of Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁸Department of Rheumatology , Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel, ⁹Tel Aviv Medical Center, Herzliya, Israel, ¹⁰Sourasky Medical Center, Petah-Tikva, Israel, ¹¹Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: The pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully elucidated. Recent evidence suggests impaired blood brain barrier (BBB) integrity as a possible mechanism…
Abstract Number: 0887 • ACR Convergence 2021
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Chrisanna Dobrowolski¹, Jiandong Su², John McGinley¹, Melissa Fazzari¹, Kathleen Bingham³, Nicole Anderson², Dorcas Beaton⁴, Lesley Ruttan³, Joan Wither², Maria Tartaglia², Mahta Kakvan², Dennisse Bonilla², May Choi⁵, Marvin Fritzler⁶, Patricia Katz⁷, Robin Green², Chaim Putterman¹ and Zahi Touma⁸, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Health Network, Toronto, ON, Canada, ³University of Toronto, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of California San Francisco, San Francisco, CA, ⁸University of Toronto, Mississauga, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments…
Abstract Number: 0988 • ACR Convergence 2021
Risk Prediction Models for Incident Systemic Lupus Erythematosus Using Lifestyle/Environmental Risk Factors and a Genetic Risk Score
Jing Cui¹, Susan Malspeis¹, May Choi², Bing Lu³, Jeffrey Sparks⁴, Kazuki Yoshida⁴ and Karen Costenbader⁵, ¹Brigham Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Belmont, MA
Background/Purpose: The identification of lifestyle/environmental and genetic factors, influencing SLE risk introduces the potential to develop risk prediction models. We examined SLE risk prediction incorporating…
Abstract Number: 1152 • ACR Convergence 2021
A Follow-Up Evaluation of a Longstanding Telephone Peer Counseling Service for People with Systemic Lupus Erythematosus and Their Loved Ones
Priscilla Toral, Roberta Horton and Jillian Rose, Hospital for Special Surgery, New York, NY
Background/Purpose: With technology rapidly evolving, studies still reinforce the value of telephone peer support for people living with chronic illness. A follow-up evaluation was conducted…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].